Evidence map›Paper›PMID 40945025›Full record

ArticleBioorganic chemistry2025

Structure-activity relationship studies on 2-thienylidene substituted 3-oxo-2,3-dihydrobenzofuran-7-carboxamides as poly (ADP-ribose) polymerase inhibitors.

Abosede Salami, Ugochi Adiele, Griffin Coate, Morgan Diolaiti, Huadong Chen, Junhao Lu, Alan Ashworth, Manisha Patil, Joshua S Fleishman, Andhavaram Ramaraju and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Abosede SalamiDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, New York 11439, United States.
Ugochi AdieleDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, New York 11439, United States.
Griffin CoateDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, New York 11439, United States.
Morgan DiolaitiUCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California 94158, United States.
Huadong ChenUCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California 94158, United States.
Junhao LuUCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California 94158, United States.
Alan AshworthUCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California 94158, United States; Department of Medicine, University of California, San Francisco, California 94158, United States.
Manisha PatilDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, New York 11439, United States.
Joshua S FleishmanDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, New York 11439, United States.
Andhavaram RamarajuDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, New York 11439, United States.
Akanksha PatelDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, New York 11439, United States.
Himaxi PatelDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, New York 11439, United States.
Ketankumar PatelDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, New York 11439, United States.
Megumi MurakamiLaboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, MD 20892, United States.
Suresh V AmbudkarLaboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, MD 20892, United States.
Tanaji T TaleleDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, New York 11439, United States. Electronic address: talelet@stjohns.edu.

Funding

Development of PARP-Isoform Selective Inhibitory Chemical ProbesSC3GM131971 · NIGMS · ST. JOHN'S UNIVERSITY · PI TALELE, TANAJI T · 2019 to 2022
$492k
NIGMS NIH HHS SC3 GM131971
6 · The paper itself

Abstract

A series of 2-thienylidene substituted 3-oxo-2,3-dihydrobenzofuran-7-carboxamide derivatives was synthesized and evaluated to investigate structure-activity relationship for inhibiting PARP1 enzyme activity. These efforts led to the identification of a new isosteric lead compound 2, (Z)-5-((7-carbamoyl-3-oxobenzofuran-2(3H)-ylidene)methyl) thiophene-2-carboxylic acid (PARP1 IC

Indexed as

BenzofuransPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesDose-Response Relationship, DrugHumansMolecular StructureStructure-Activity RelationshipBenzofuransPARP1 protein, humanPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) Polymerases3-oxo-2,3-dihydrobenzofuran-7-carboxamideABC transportersDockingIn vitro ADMEKnoevenagel condensationPARP1PARylationThienylidene

Identifiers

PMID40945025
PMCPMC12478838

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.